TB-500 research overview

TB-500 refers to the synthetic form of the active fragment of Thymosin Beta-4 (Tβ4), a 43-amino-acid actin-sequestering protein. The synthetic fragment corresponds to amino acids 17–23 of Tβ4 (Ac-LKKTETQ). CAS: 885340-08-9.

Thymosin Beta-4 is produced by platelets, white blood cells and other cell types and is released in high concentrations following tissue injury. Research has focused on its role as a promoter of angiogenesis, cellular migration, and inflammatory regulation.

TB-500 functions primarily through its interaction with G-actin (globular actin). By binding monomeric actin and preventing its polymerisation into F-actin filaments, Tβ4 regulates cytoskeletal dynamics critical to cell migration.

In wound healing models, this promotes keratinocyte and endothelial cell migration into wound margins. TB-500 also appears to upregulate matrix metalloproteinases (MMPs) and downregulate inflammatory mediators, facilitating extracellular matrix remodelling.

Published rodent and large animal studies have examined TB-500 in:

• Cardiac muscle repair following myocardial infarction (mouse/rat)
• Dermal wound healing (full-thickness excision models)
• Corneal repair
• Traumatic brain injury (mouse)
• Tendon injury (horse — naturally occurring Tβ4)

As with other research peptides, translation to human clinical outcomes has not been established and no human clinical data exists.

Store lyophilized TB-500 at −20 °C. Reconstitute with bacteriostatic water immediately before use. Reconstituted solutions are stable for 28 days at 4 °C. Avoid light exposure and repeated freeze-thaw.